Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint pha
about
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint pha
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Efficacy and safety of ipragli ...... ticentre, blinded-endpoint pha
@en
Efficacy and safety of ipragli ...... ticentre, blinded-endpoint pha
@nl
type
label
Efficacy and safety of ipragli ...... ticentre, blinded-endpoint pha
@en
Efficacy and safety of ipragli ...... ticentre, blinded-endpoint pha
@nl
prefLabel
Efficacy and safety of ipragli ...... ticentre, blinded-endpoint pha
@en
Efficacy and safety of ipragli ...... ticentre, blinded-endpoint pha
@nl
P2093
P2860
P1433
P1476
Efficacy and safety of ipragli ...... ticentre, blinded-endpoint pha
@en
P2093
Daigaku Uchida
Ichiro Tatsuno
Kazuki Kobayashi
Ko Ishikawa
Koutaro Yokote
Masaya Koshizaka
Minoru Takemoto
Naotake Hashimoto
Nobuichi Kuribayashi
PRIME-V Study Investigators
P2860
P304
P356
10.1136/BMJOPEN-2016-015766
P577
2017-05-09T00:00:00Z